Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01201850 · ClinicalTrials.gov registry record · NA
The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
A NA study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT01201850: Clinical Trial NA study, sponsored by University of Colorado, Denver.
NCT01201850 is a NA study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01201850, a NA study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study is being done to learn about the safety of the study drug bevacizumab(Avastin®), when used to treat radiation necrosis. The primary objective of this study is to test the feasibility of treating Central Nervous System (CNS) tumor patients suffering from radiation necrosis with bevacizumab every 2 weeks. The secondary objectives of this study are: * To evaluate improvement in neurologic symptoms associated with bevacizumab as assessed by clinical evaluation; * To investigate the neuro-imaging changes in radiation necrosis associated edema, including Mass Resonance (MR) spectroscopy; * To evaluate changes in corticosteroid use in patients with radiation necrosis following treatment with bevacizumab; * To evaluate changes in quality of life.
Primary Outcome
This pilot study was designed to evaluate the feasibility of treating pediatric patients with CNS radiation necrosis with bevacizumab. Patients enrolled on study were assessed for number of doses of bevacizumab that they received while on study. Participants who successfully received at least 5 of the 6 planned doses of bevacizumab (IV every 2 weeks) without significant events were determined to have met the outcome measure.
Interventions
- DRUG Bevacizumab (Avastin®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-06-28 |
| Est. Completion | 2016-08-04 |
| Phase | NA |
Why NCT01201850 stopped before completion
NCT01201850 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab (Avastin®) is the first listed.
NCT01201850 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01201850 about?
NCT01201850 is a clinical study titled "The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors". This study is being done to learn about the safety of the study drug bevacizumab(Avastin®), when used to treat radiation necrosis. The primary objective of this study is to test the feasibility of treating Central Nervous System (CNS) tumor patients suffering from radiation necrosis with bevacizuma...
What is the current status of trial NCT01201850?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2010-06-28. Estimated completion is 2016-08-04.
What interventions are being tested in trial NCT01201850?
The interventions under investigation include: Bevacizumab (Avastin®) (DRUG).
Who is sponsoring clinical trial NCT01201850?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01201850's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI